Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 7/2017

Open Access 01-07-2017 | Review

When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development

Authors: Nektarios Oraiopoulos, William C. N. Dunlop

Published in: Advances in Therapy | Issue 7/2017

Login to get access

Abstract

Introduction

The purpose of this study was to identify the key barriers to a customer-focused drug development process and develop a comprehensive framework to overcome them.

Methods

The paper draws on existing literature, both academic and practitioner, across a range of disciplines (innovation management, marketing, organizational behavior, behavioral economics, health economics, industry reports). On the basis of this extensive review, a conceptual framework is developed that offers concrete suggestions on how organizations can overcome the barriers and enable a more customer-focused development process.

Results

The barriers to collaboration are organized into three distinct categories (economic, behavioral, organizational), and within each category, a one-to-one mapping between barriers and solutions is developed.

Conclusion

The framework is specifically designed with the objective of offering actionable and practical advice to executives who face these challenges in their organizations. The paper provides a unique theoretical contribution by synthesizing findings from several academic disciplines with concrete examples from the pharmaceutical industry.

Funding

Mundipharma International Limited.
Literature
1.
2.
3.
Rao A, Purkayastha D. “Exubera fiasco: what went wrong?”, teaching note 508-115-8. Hyderabad: ICMR Center for Management Research; 2008.
4.
5.
6.
Harrison RK. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15(12):817–8.CrossRefPubMed
7.
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.CrossRefPubMed
8.
Griffin A, Hauser JR. Patterns of communication among marketing, engineering and manufacturing—a comparison between two new product teams. Manag Sci. 1992;38(3):360–73.CrossRef
9.
Olson EM, Walker OC Jr, Ruekert RW, Bonner JM. Patterns of cooperation during new product development among marketing, operations and R&D: implications for project performance. J Prod Innov Manag. 2001;18(4):258–71.CrossRef
10.
Slater SF, Mohr JJ, Sengupta S. Radical product innovation capability: literature review, synthesis, and illustrative research propositions. J Prod Innov Manag. 2014;31(3):552–66.CrossRef
11.
Calantone RJ, Schmidt JB, Di Benedetto CA. New product activities and performance: the moderating role of environmental hostility. J Prod Innov Manag. 1997;14(3):179–89.CrossRef
12.
DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–7.CrossRefPubMed
13.
Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8(12):959–68.CrossRefPubMed
14.
Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17(9/10):419–24.CrossRefPubMed
15.
Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–31.CrossRefPubMed
16.
17.
Hauser JR, Simester DI, Wernerfelt B. Internal customers and internal suppliers. J Mark Res. 1996;33(3):268–80.CrossRef
18.
Souder WE. Achieving organizational consensus with respect to R&D project selection criteria. Manag Sci. 1975;21(6):669–81.CrossRef
19.
Dougherty D. Interpretive barriers to successful product innovation in large firms. Organ Sci. 1992;3(2):179–202.CrossRef
20.
Cooper RG. Third-generation new product processes. J Prod Innov Manag. 1994;11(1):3–14.CrossRef
21.
Sharpe P, Keelin T. How SmithKline Beecham makes better resource-allocation decisions. Harv Bus Rev. 1997;76(2):45–6.
22.
Cooper RG. Winning at new products: accelerating the process from idea to launch. Cambridge: Addison-Wesley; 2001.
23.
Royer I. Why bad projects are so hard to kill. Harv Bus Rev. 2003;81(2):48–56.PubMed
24.
Staw BM. Knee-deep in the big muddy: a study of escalating commitment to a chosen course of action. Organ Behav Hum Perform. 1976;16:27–44.CrossRef
25.
Bazerman MH, Beekun RI, Schoorman FD. Performance evaluation in a dynamic context: a laboratory study of the impact of a prior commitment to the rate. J Appl Psychol. 1982;67(6):873–6.CrossRef
26.
Bazerman MH, Giuliano T, Appelman A. Escalation of commitment in individual and group decision making. Organ Behav Hum Perform. 1984;33(2):141–52.CrossRef
27.
Jonas E, Schulz-Hardt S, Frey D, Thelen N. Confirmation bias in sequential information search after preliminary decisions: an expansion of dissonance theoretical research on selective exposure to information. J Pers Soc Psychol. 2001;80(4):557–71.CrossRefPubMed
28.
Bolton LE. Stickier priors: the effects of nonanalytic versus analytic thinking in new product forecasting. J Mark Res. 2003;40(1):65–79.CrossRef
29.
Biyalogorsky E, Boulding W, Staelin R. Stuck in the past: why managers persist with new product failures. J Mark. 2006;70:108–21.CrossRef
30.
Russo JE, Schoemaker PJH. Managing overconfidence. Sloan Manag Rev. 1992;33(2):7–17.
31.
Janis IL. Groupthink: psychological studies of policy decisions and fiascoes. Boston: Houghton Mifflin; 1982.
32.
Hansen MT, Mors ML, Løvås B. Knowledge sharing in organizations: multiple networks, multiple phases. Acad Manag J. 2005;48(5):776–93.CrossRef
33.
Hansen MT, Løvås B. How do multinational companies leverage technological competencies? Moving from single to interdependent explanations. Strateg Manag J. 2004;25(8/9):801–22.CrossRef
34.
Casciaro T, Lobo MS. Competent jerks, lovable fools, and the formation of social networks. Harv Bus Rev. 2005;83(6):92–9.PubMed
35.
Zander U, Kogut B. Knowledge and the speed of the transfer and imitation of organizational capabilities: an empirical test. Organ Sci. 1995;6(1):76–92.CrossRef
36.
Szulanski G. Exploring internal stickiness: impediments to the transfer of best practice within the firm. Strateg Manag J. 1996;17(S2):27–43.CrossRef
37.
Azoulay P, Zivin JSG, Manso G. Incentives and creativity: evidence from the academic life sciences. RAND J Econ. 2011;42(3):527–54.CrossRef
38.
Ederer F, Manso G. Is pay for performance detrimental to innovation? Manag Sci. 2013;59(7):1496–513.CrossRef
39.
Tian X, Wang TY. Tolerance for failure and corporate innovation. Rev Financ Stud. 2014;27(1):211–55.CrossRef
40.
Loch CH, Tapper UAS. Implementing a strategy-driven performance measurement system for an applied research group. J Prod Innov Manag. 2002;19(3):185–98.CrossRef
41.
Terwiesch C, Ulrich K. Managing the opportunity portfolio. Res Technol Manag. 2008;51(5):27–38.
42.
Loch C, Kavadias S. Implementing strategy through projects. In: Morris PWG, Pinto J, Söderlund J, editors. The Oxford handbook of project management. Oxford: Oxford University Press; 2011. p. 224–51.
43.
Birkinshaw J. Strategies for managing internal competition. Calif Manag Rev. 2001;44(1):21–38.CrossRef
44.
Schlapp J, Oraiopoulos N, Mak V. Resource allocation decisions under imperfect evaluation and organizational dynamics. Manag Sci. 2015;61(9):2139–59.CrossRef
45.
Huckman RS, Pisano GP, Rennella M. Wyeth pharmaceuticals: spurring scientific creativity with metrics. Harvard Business School Case 607-008. 2010.
46.
Lovallo D, Kahneman D. Delusions of success: how optimism undermines executives’ decisions. Harv Bus Rev. 2003;81(7):56–63.PubMed
47.
Hammond JS, Keeney RL, Raiffa H. The hidden traps in decision making. Harv Bus Rev. 1998;76(5):47–58.PubMed
48.
Sengupta K, Abdel-Hamid TK, Van Wassenhove LN. The experience trap. Harv Bus Rev. 2008;86(2):94–101.PubMed
49.
50.
Christensen C, Hall T, Dillon K, Duncan D. Know your customers’ “jobs to be done”. Harv Bus Rev. 2016;94(9):54–62.
51.
Sullivan W, Hirst M, Beard S, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ. 2016;17(6):755–70.CrossRefPubMed
52.
Hansen MT. Collaboration: how leaders avoid the traps, create unity, and reap big results. Boston: Harvard Business Press; 2009.
53.
54.
Hansen MT, von Oetinger B. Introducing T-shaped managers: knowledge management’s next generation. Harv Bus Rev. 2001;79(3):106–16.PubMed
55.
Hansen MT, Nohria N, Tierney T. What’s your strategy for managing knowledge? Harv Bus Rev. 1999;77(2):106–16.PubMed
56.
Troy LC, Hirunyawipada T, Paswan AK. Cross-functional integration and new product success: an empirical investigation of the findings. J Mark. 2008;72(6):132–46.CrossRef
57.
Kim WC, Mauborgne R. Fair process: managing in the knowledge economy. Harv Bus Rev. 2003;81(1):127–36.
Metadata
Title
When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development
Authors
Nektarios Oraiopoulos
William C. N. Dunlop
Publication date
01-07-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0567-y

Other articles of this Issue 7/2017

Advances in Therapy 7/2017 Go to the issue

Original Research

The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study

Review

Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials

Letter

Comment on Rosenberg J, et al.: “Deep Neuromuscular Blockade Improves Laparoscopic Surgical Conditions: A Randomized, Controlled Study”

Original Research

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Review

A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders

Original Research

Duration of Antiviral Prophylaxis and Risk of Herpes Zoster among Patients Receiving Autologous Hematopoietic Stem Cell Transplants: A Retrospective, Observational Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits